Insulin glargine biosimilar - Samsung Bioepis/Merck & Co.

Drug Profile

Insulin glargine biosimilar - Samsung Bioepis/Merck & Co.

Alternative Names: MK 1293; SB 9

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator Samsung Bioepis
  • Developer Merck & Co; Samsung Bioepis
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Diabetes mellitus; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 16 Sep 2016 Sanofi files a patent infringement suit against Merck Sharp & Dohme in the US District Court for the District of Delaware
  • 05 Aug 2016 Preregistration for Type-1 diabetes mellitus in USA (SC)
  • 05 Aug 2016 Preregistration for Type-2 diabetes mellitus in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top